|
gptkbp:instanceOf
|
gptkb:naphthoylindole
gptkb:synthetic_cannabinoid
|
|
gptkbp:affinityForCB1
|
383 nM
|
|
gptkbp:affinityForCB2
|
13.8 nM
|
|
gptkbp:agonistOf
|
gptkb:CB1_receptor
gptkb:CB2_receptor
|
|
gptkbp:CASNumber
|
210179-46-7
|
|
gptkbp:category
|
gptkb:recreational_drug
research chemical
|
|
gptkbp:chemicalFormula
|
C24H23NO
|
|
gptkbp:discoveredBy
|
gptkb:John_W._Huffman
|
|
gptkbp:effect
|
psychoactive effects
analgesic effects
immunomodulatory effects
cannabinoid receptor activation
|
|
gptkbp:firstSynthesized
|
1990s
|
|
gptkbp:IUPACName
|
(2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone
|
|
gptkbp:legalStatus
|
gptkb:Class_B_(UK)
Schedule I controlled substance (USA)
illegal (China)
|
|
gptkbp:molecularWeight
|
341.45 g/mol
|
|
gptkbp:namedAfter
|
gptkb:John_W._Huffman
|
|
gptkbp:PubChem_CID
|
CHEMBL2105932
44418354
|
|
gptkbp:relatedTo
|
gptkb:JWH-018
gptkb:JWH-073
gptkb:JWH-133
|
|
gptkbp:routeOfAdministration
|
oral
inhalation
intraperitoneal injection
|
|
gptkbp:UNII
|
6K1V7S2F3E
|
|
gptkbp:usedIn
|
gptkb:scientific_research
|
|
gptkbp:bfsParent
|
gptkb:JWH_cannabinoids
|
|
gptkbp:bfsLayer
|
6
|
|
http://www.w3.org/2000/01/rdf-schema#label
|
JWH-015
|